🇺🇸 FDA

Company profile · Sponsor

Forte

Forte Biosciences

FBRX · NYSE pharma DALLAS, TX, USA
Pipeline
5
Drugs
0
Patents
3

Quick answer

Forte (FBRX) is a pharma company. headquartered in DALLAS, TX, USA. listed on NYSE. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 3 patents to this profile..

Company facts

Ticker FBRX
Exchange NYSE
Company type pharma
Headquarters DALLAS, TX, USA
SEC CIK 0001419041

Pipeline (5)

Search pipeline →

  1. FB-401

    Forte

    Atopic Dermatitis

    phase 2 mab terminated

    2 trials

  2. FB102

    Forte

    Celiac Disease

    phase 2 mab active

    1 trial

  3. FB102

    Forte

    Alopecia Areata

    phase 1 small molecule active

    1 trial

  4. FB102

    Forte

    Vitiligo

    phase 1 small molecule active

    1 trial

  5. Signature Cord Prime

    Forte

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial

Patents (3)

Search patents →

  1. US 11891389

    PGDH inhibitors and methods of making and using

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11345702

    PGDH inhibitors and methods of making and using

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10973841

    Compositions for the treatment of skin conditions

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Forte?

Forte (FBRX) is a pharma company. headquartered in DALLAS, TX, USA. listed on NYSE. NovaPharmaNews links 5 pipeline programs, 0 drugs, and 3 patents to this profile..

What pipeline programs does Forte sponsor?

We track 5 ClinicalTrials.gov-linked programs for Forte, including FB-401 and 4 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Forte company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.